Lexeo Therapeutics (LXEO) Chardan's 8th Annual Genetic Medicines Conference summary

Program overviews and upcoming catalysts

• Three clinical-stage gene therapy programs target genetic cardiac diseases and APOE4-associated Alzheimer's, with all expecting near-term data readouts.

• Friedreich's ataxia (FA) program focuses on cardiac pathology, with recent data showing reductions in left ventricular mass index (LVMI), wall thickness, and troponin.

• Arrhythmogenic cardiomyopathy (PKP2) program is in clinical trials, with upcoming data on safety, biodistribution, and early efficacy biomarkers.

• APOE4 homozygous Alzheimer's program completed phase I enrollment, with a data readout imminent, focusing on APOE2 expression and Alzheimer's biomarkers.

• Regulatory updates and pivotal study planning are expected this year, particularly for the FA program.

Friedreich's ataxia program details

• Data showed 11.4% reduction in LVMI and 14% reduction in wall thickness, both considered clinically meaningful.

• Troponin levels reduced by 50%, surpassing the 30% threshold for clinical significance.

• Frataxin expression is being optimized, with a goal of exceeding 5% of normal by LC-MS and 40% of cells by IHC.

• Study design includes a broad patient population, supporting potential for wide label and commercial use.

• Regulatory engagement is ongoing, with LVMI as the likely pivotal endpoint due to its correlation with mortality.

Arrhythmogenic cardiomyopathy (PKP2) program

• Targets a 60,000-patient rare disease in the US, with no approved therapies.

• Preclinical models show restoration of plakophilin 2 reverses mortality and reduces arrhythmias.

• Clinical trial includes two dose cohorts, focusing on safety, protein expression, and efficacy biomarkers like PVCs.

• Early readouts will emphasize safety and biodistribution, with efficacy signals expected to evolve over time.

• Differentiation from other gene therapies may arise from vector serotype and expression profiles.